BAY2666605 for Metastatic Melanoma and Other Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Metastatic Melanoma and Other Solid Tumors+1 More
BAY2666605 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is being done to learn more about a new substance called BAY2666605 that may help treat advanced cancer by triggering cell death.

Eligible Conditions
  • Metastatic Melanoma and Other Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

7 Primary · 5 Secondary · Reporting Duration: Up to 28 + 14 days

Cycle 1 Day 1
Maximal plasma exposure (Cmax) of BAY2666605
Cycle 1, Day 1
AUC(0-24) of BAY2666605
Cycle 1, Day 15
AUC(0-24)md of BAY2666605
Cmax,md of BAY2666605
Day 14
The incidence of DLTs at each dose level in the Dose Escalation part of the study
Month 6
DCR
DOR
Incidence and severity of TEAEs including TESAEs
ORR
OS
PFS by investigator assessment
RP2D of BAY2666605

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

Dose expansion of BAY2666605
1 of 2
Dose escalation of BAY2666605
1 of 2

Experimental Treatment

89 Total Participants · 2 Treatment Groups

Primary Treatment: BAY2666605 · No Placebo Group · Phase 1

Dose expansion of BAY2666605
Drug
Experimental Group · 1 Intervention: BAY2666605 · Intervention Types: Drug
Dose escalation of BAY2666605
Drug
Experimental Group · 1 Intervention: BAY2666605 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 28 + 14 days

Who is running the clinical trial?

BayerLead Sponsor
2,140 Previous Clinical Trials
23,767,868 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
is not required This means that you do not need to sign a form in order to be screened for a genetic disorder.
were invited to participate People with melanoma, glioblastoma/anaplastic astrocytoma, sarcoma, or epithelial ovarian cancer/fallopian tube/primary peritoneal cancer were invited to participate in the study.
and frozen tumor tissue We have a total of 5-10 pieces of archival tumor tissue that we can use for prescreening, and an additional 20 pieces that we can use for screening.
suggests poor prognosis The expression of SLFN12/PDE3A in archival tumour samples suggests a poor prognosis.
At least 12 weeks of life is expected.
Some people with advanced or metastatic cancer treated with all available standard therapies experience disease progression, which is documented through radiological exams.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: November 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.